Research & Development
US FDA Approves Opioid-free Pain Med Orphengesic Forte by Galt Pharmaceuticals
29 July 2020 - - US-based pharmaceutical company Galt Pharmaceuticals has received a new drug approval to offer a non-opioid, non-controlled, non-addictive alternative for healthcare providers to manage patients suffering from pain, the company said.

On July 8, 2020 the US Food and Drug Administration approved the company's Supplemental Abbreviated New Drug Application for Orphengesic Forte, over two months ahead of the scheduled goal date.

Orphengesic Forte is indicated for the relief of mild to moderate pain of acute musculoskeletal disorders, paired with rest, physical therapy and other measures.

The Centers for Disease Control and Prevention reports 20% of US adults are affected by chronic pain one of the most common reasons adults seek medical care.

Galt Pharmaceuticals has created a unique pharmaceutical franchise or "Phranchise" concept that moves product representation away from corporate headquarters into local communities.

Phranchises provide education to local healthcare providers while Galt manages functions such as drug research, regulatory approval, compliance and supply chain.


Related Headlines